Specialist RNA process developer eTheRNA Manufacturing has introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.
This new LNP service uses eTheRNA’s proprietary lipid libraries and formulations to facilitate targeted delivery and tailored biodistribution solutions. Through working with the company’s specialist team, the service has been designed to allow customers to maximise the delivery of their RNA-products.
The platform
eTheRNA Manufacturing’s LNP formulation platforms employ a range of mRNA and lipid mixing technologies and looks to provide the market with differentiated alternatives to the LNP formulations currently in use. The company can also provide phase-appropriate analytical development in parallel with manufacturing process optimisation to further assist customers with their RNA product development programmes.
Official comments
Bernard Sagaert, COO and Senior VP of Manufacturing at eTheRNA Manufacturing, said: “The recent Covid-19 pandemic has facilitated the rapid development and approval of the first-wave of Covid-19 RNA vaccines, which has led some people to underestimate some of the complexities of developing a RNA-based therapeutic or vaccine. Development of efficacious and safe RNA-based medicines requires a unique set of skills and resources to simultaneously advance both the active drug substance and the correct formulation required for the drug product. Through our long-established focus on RNA manufacture and delivery, and associated proprietary technologies, we have engineered libraries of custom lipids, which enables our LNP formulation team to design the most appropriate LNP for your mRNA application.”
